Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study of clinical features and an analysis of gait with floor reaction forces and EMG of leg flexors and extensors were made in patients with multiple cerebral infarction or patients with Parkinson's disease having frozen gait. A case with occlusion of the bilateral anterior cerebral arteries resulting in massive infarction of the infero-medial part of the frontal lobes was also studied as he showed a unique disorder characterized by apraxia of gait. Frozen gait is characterized by shuffling steps, broad-based stance, positive foot grasp, kinesia paradoxa and disturbance of postural reflexes. The vector angle which shows foot pressure in forward locomotion was decreased in patients with frozen gait. EMGs of lower leg muscles in frozen gait were grouping of potentials corresponding to the shuffle and reciprocity between flexors and extensors was preserved. The patient with infarction of the bilateral anterior cerebral arteries showed a peculiar disorder of gait which was characterized by an inability to initiate stepping. It is considered as "apraxia of gait" in a classical sense, which differs from frozen gait. Observation of this patient suggests that the infero-medical part of the frontal lobe plays an important role in the initiation of gait. Furthermore, common features of frozen gait in patients with Parkinson's disease and in patients with multiple cerebral infarction involving the frontal lobe suggest that the nigrostriatal structures and the frontal lobe are important in CNS mechanisms subserving smooth locomotion.
 ...
PMID:[Clinical and physiological study of apraxia of gait and frozen gait]. 275 55

L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) was administered at a maintenance dose of 600-900 mg/day, in 10 patients with Parkinson's disease who exhibited a notable freezing phenomenon under the medication of L-DOPA/DCI (DOPA-decarboxylase inhibitor). Changes in clinical symptoms were examined after 8 weeks of treatment. Frozen gait and dysarthria were markedly alleviated by L-threo-DOPS administration, and the rigidity persisting under conventional medication was also relieved. Marked improvement in frozen gait was observed in 1-2 weeks, and that of dysarthria in 2-3 weeks, after the initiation of L-threo-DOPS administration. Nine of the 10 patients were treated with a combination of DOPA and DCI, and the L-threo-DOPS/benserazide ratio and L-threo-DOPS/carbidopa ratio were 9.2 and 26.3, respectively. The effect of L-threo-DOPS were enhanced in one patient in whom DCI was changed from carbidopa to benserazide, suggesting the necessity of further studies on the type and dose of DCI to be combined with L-threo-DOPS.
 ...
PMID:L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease. 393 72